性与生殖健康领域谁付费、有何回报?干预措施的成本与成本效果综述及对未来筹资与市场的影响
该系列论文综述性与生殖健康及权利干预的筹资、成本与成本效果,分析未来资金增减的可能影响,并从经济学角度提出政策与监管建议。针对HIV和性传播感染、避孕及堕胎护理的干预是全球最具成本效果的卫生干预之一,但资金严重紧张。
要点
- 针对HIV和性传播感染、避孕及堕胎护理的干预是全球最具成本效果的卫生干预之一。
- HIV治疗与预防及避孕药具严重依赖捐赠资金,自2017年以来下降;2025年初美国国际开发署资金终止,受影响国家需以更少资源做更多事。
核心结论
- 针对HIV和性传播感染、避孕干预和堕胎护理的干预是全球最具成本效果的卫生干预之一,但其资金正面临严重压力。
- HIV治疗与预防及避孕药具严重依赖捐赠资金,自2017年以来捐赠资金已下降。
- 2025年初美国国际开发署资金终止,要求受影响最严重的国家今后以少得多的资源做更多的事。
研究设计与样本
- 本文为系列论文,总结性与生殖健康及权利干预的筹资、成本与成本效果,分析未来资金增减的可能影响,并从经济学角度提出政策与监管建议。
主要发现
- HIV治疗与预防及避孕药具严重依赖捐赠资金,捐赠资金自2017年以来下降。
关键数值与推荐
- 针对HIV和性传播感染、避孕干预和堕胎护理的干预被评为全球最具成本效果的卫生干预之一。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This Series paper provides a summary of what is known about the funding, cost, and cost-effectiveness of sexual and reproductive health and rights interventions, interrogates the likely impacts of increasing or reducing future sexual and reproductive health and rights funding, and provides recommendations for policy and regulatory changes from an economic perspective. Interventions that target HIV and sexually transmitted infections, contraceptive interventions, and abortion care are among the most cost-effective health interventions worldwide, but their funding is under severe duress. In 2023, approximately US$35 billion was spent on these intervention areas across low-income and middle-income countries-only two-thirds of the $52 billion needed per year. HIV treatment and prevention, as well as contraceptive commodities, rely heavily on donor funding, which has decreased since 2017. The discontinuation of the US Agency for International Development funding in early 2025, in particular, requires that the most impacted countries will have to do more with much less going forward.
引用
- Meyer-Rath G, Jamieson L, Mudimu E, et al. Who pays and what pays off in sexual and reproductive health? A review of the cost and cost-effectiveness of interventions and implications for future funding and markets. Lancet. 2025. PMID: 41176394. doi:10.1016/S0140-6736(25)01724-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。